Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;22(6):527-32.
doi: 10.1097/MOH.0000000000000183.

Autologous platelet-rich plasma: evidence for clinical use

Claudia S Cohn  1 , Evelyn Lockhart
Affiliations
Review

Autologous platelet-rich plasma: evidence for clinical use

Claudia S Cohn et al. Curr Opin Hematol. 2015 Nov.

Abstract

Purpose of review: Autologous platelet-rich plasma (aPRP) is growing in popularity as a therapy to augment wound healing, speed the recovery from muscle and joint injuries, and enhance recovery after surgical repair. High-profile athletes treated with aPRP have increased the demand from the general population. Yet, evidence to support the use of aPRP in most clinical settings is weak, because of poorly controlled clinical trials.

Recent findings: Preparations of aPRP vary by platelet count, leukocyte content, and degree of platelet activation. Nonetheless, these heterogeneous preparations are used in trials to assess the efficacy of aPRP treatment.

Summary: Despite weak evidence, the use of aPRP continues to grow. High-quality randomized controlled trials are needed to validate or repudiate the potential efficacy of aPRP. Standards for aPRP preparation and quality should be created.

PubMed Disclaimer

Publication types